JP2017524735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524735A5 JP2017524735A5 JP2017522324A JP2017522324A JP2017524735A5 JP 2017524735 A5 JP2017524735 A5 JP 2017524735A5 JP 2017522324 A JP2017522324 A JP 2017522324A JP 2017522324 A JP2017522324 A JP 2017522324A JP 2017524735 A5 JP2017524735 A5 JP 2017524735A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- composition
- acceptable salt
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 150000001875 compounds Chemical group 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 125000005418 aryl aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 5
- 229960002756 Azacitidine Drugs 0.000 claims 5
- 102000003964 Histone deacetylases Human genes 0.000 claims 5
- 108090000353 Histone deacetylases Proteins 0.000 claims 5
- 206010024324 Leukaemias Diseases 0.000 claims 5
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 5
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 5
- 102100007189 HDAC6 Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 101700002249 HDAC6 Proteins 0.000 claims 2
- 108010023925 Histone Deacetylase 6 Proteins 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *N(CCCCCCC(NO)=O)C(c1cnc(N(*)/C2=C/C/C=C/C=C/C2)nc1)=O Chemical compound *N(CCCCCCC(NO)=O)C(c1cnc(N(*)/C2=C/C/C=C/C=C/C2)nc1)=O 0.000 description 3
- VLIUIBXPEDFJRF-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c(cccc2)c2Cl)nc1)=O)=O VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 3
- QGZYDVAGYRLSKP-UHFFFAOYSA-N ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O Chemical compound ONC(CCCCCCNC(c1cnc(N(c2ccccc2)c2ccccc2)nc1)=O)=O QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 3
Claims (16)
- 治療に有効な量のヒストンデアセチラーゼ６（ＨＤＡＣ６）特異的阻害剤または製薬上許容できるその塩、及びアザシチジンまたは製薬上許容できるその塩を含む、白血病を治療するための薬学的組み合わせであって、
前記ＨＤＡＣ６特異的阻害剤は、式Ｉの化合物：
環Ｂはアリールまたはヘテロアリールであり、
Ｒ １ はアリールまたはヘテロアリールであり、これらはそれぞれ、ＯＨ、ハロゲン、またはＣ １−６ −アルキルによって任意に置換されていてよく、かつ
ＲはＨまたはＣ １−６ −アルキルである。）
または製薬上許容できるその塩である、白血病を治療するための薬学的組み合わせ。 - 前記白血病は急性骨髄性白血病（ＡＭＬ）である、請求項１に記載の組み合わせ。
- 前記式Ｉの化合物は、
- 前記式Ｉの化合物は、
- 前記組み合わせは、製薬上許容できる担体を更に含む、請求項１に記載の組み合わせ。
- 白血病を治療するための組成物であって、治療に有効な量のヒストンデアセチラーゼ６（ＨＤＡＣ６）特異的阻害剤または製薬上許容できるその塩、及びアザシチジンまたは製薬上許容できるその塩を含有し、
前記ＨＤＡＣ６特異的阻害剤は、式Ｉの化合物：
環Ｂはアリールまたはヘテロアリールであり、
Ｒ １ はアリールまたはヘテロアリールであり、これらはそれぞれ、ＯＨ、ハロゲン、またはＣ １−６ −アルキルによって任意に置換されていてよく、かつ
ＲはＨまたはＣ １−６ −アルキルである。）
または製薬上許容できるその塩である、組成物。 - 前記白血病は急性骨髄性白血病（ＡＭＬ）である、請求項６に記載の組成物。
- 前記式Ｉの化合物は、
- 前記式Ｉの化合物は、
- 急性骨髄性白血病を治療するための組成物であって、治療に有効な量の式Ｉの化合物：
環Ｂはアリールまたはヘテロアリールであり、
Ｒ１はアリールまたはヘテロアリールであり、これらはそれぞれ、ＯＨ、ハロゲン、またはＣ１−６−アルキルにより任意に置換されてよく、かつ
ＲはＨまたはＣ１−６−アルキルである。）
または製薬上許容できるその塩を含有する、組成物。 - 前記式Ｉの化合物は、
- 前記式Ｉの化合物は、
- 前記組成物は、アザシチジンを更に含む、請求項１０〜１２のいずれか一項に記載の組成物。
- ＨＤＡＣ６特異的阻害剤及びアザシチジンを含む組み合わせの、癌細胞の細胞生存能を低下させるための使用。
- ＨＤＡＣ６特異的阻害剤及びアザシチジンを含む組み合わせの、癌細胞の分化を誘発するための使用。
- ＨＤＡＣ６特異的阻害剤及びアザシチジンを含む組み合わせの、癌細胞のアポトーシスを誘発するための使用。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021473P | 2014-07-07 | 2014-07-07 | |
| US62/021,473 | 2014-07-07 | ||
| US201462061233P | 2014-10-08 | 2014-10-08 | |
| US62/061,233 | 2014-10-08 | ||
| US201562147218P | 2015-04-14 | 2015-04-14 | |
| US62/147,218 | 2015-04-14 | ||
| PCT/US2015/039225 WO2016007423A1 (en) | 2014-07-07 | 2015-07-06 | Treatment of leukemia with histone deacetylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524735A JP2017524735A (ja) | 2017-08-31 |
| JP2017524735A5 true JP2017524735A5 (ja) | 2018-08-02 |
| JP6952602B2 JP6952602B2 (ja) | 2021-10-20 |
Family
ID=55064739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522324A Active JP6952602B2 (ja) | 2014-07-07 | 2015-07-06 | ヒストンデアセチラーゼ阻害剤による白血病の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9833466B2 (ja) |
| EP (1) | EP3166603B1 (ja) |
| JP (1) | JP6952602B2 (ja) |
| KR (1) | KR20170044097A (ja) |
| CN (1) | CN107205988A (ja) |
| AU (1) | AU2015288060A1 (ja) |
| BR (1) | BR112017000301A2 (ja) |
| CA (1) | CA2954522A1 (ja) |
| EA (1) | EA201790142A1 (ja) |
| IL (1) | IL249935A0 (ja) |
| MX (1) | MX2017000307A (ja) |
| SG (1) | SG11201700094TA (ja) |
| WO (1) | WO2016007423A1 (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012008553A (es) | 2010-01-22 | 2012-11-30 | Acetylon Pharmaceuticals Inc | Compuestos de amida inversa como inhibidores de proteina desacetilasa y metodos de uso de los mismos. |
| JP2015515279A (ja) | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| US9403779B2 (en) * | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| EA201691155A1 (ru) | 2013-12-03 | 2016-09-30 | Эситайлон Фармасьютикалз, Инк. | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| JP6693957B2 (ja) | 2014-12-12 | 2020-05-13 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｈｄａｃ１／２阻害剤としてのピペリジン誘導体 |
| WO2016172734A1 (en) * | 2015-04-24 | 2016-10-27 | California Institute Of Technology | Reactivation of x chromosome genes |
| AR105812A1 (es) | 2015-06-08 | 2017-11-15 | Acetylon Pharmaceuticals Inc | Métodos para la preparación de inhibidores de proteína deacetilasa |
| JP6816036B2 (ja) | 2015-06-08 | 2021-01-20 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストン脱アセチル化阻害剤の結晶形態 |
| WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
| TW201803594A (zh) | 2016-06-09 | 2018-02-01 | 達納-法伯癌症協會 | Hdac抑制劑與bet抑制劑之使用方法及醫藥組合 |
| ES2929032T3 (es) | 2016-08-08 | 2022-11-24 | Acetylon Pharmaceuticals Inc | Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos |
| US11197881B2 (en) | 2016-10-27 | 2021-12-14 | California Institute Of Technology | HDAC inhibitor compositions for reactivation of the X chromosome |
| WO2018098168A1 (en) | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof |
| CN106810460A (zh) * | 2016-12-30 | 2017-06-09 | 苏州诚和医药化学有限公司 | 一种4‑[2‑(二甲基氨基)乙氧基]苄胺的制备方法 |
| WO2019084434A1 (en) | 2017-10-26 | 2019-05-02 | National University Of Singapore | NEW APPROACH FOR UNIVERSAL MONITORING OF MINIMUM RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA |
| JP7021503B2 (ja) * | 2017-11-02 | 2022-02-17 | 三菱瓦斯化学株式会社 | 脂肪族ジアミンの製造方法 |
| CN116421598A (zh) * | 2022-01-11 | 2023-07-14 | 苏州亚盛药业有限公司 | 用于治疗aml-mrc和mds的方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549633A (en) | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| AU2001248701A1 (en) | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2002074298A1 (fr) | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de production d'il-6 |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| IL161661A0 (en) | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| DK1485354T3 (da) | 2002-03-13 | 2008-09-01 | Janssen Pharmaceutica Nv | Sulfonylamino-derivater som nye inhibitorer af histandeacetylase |
| DK1485353T3 (da) | 2002-03-13 | 2011-11-28 | Janssen Pharmaceutica Nv | Nye inhibitorer af histondeacetylase |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| ES2279395T3 (es) | 2003-07-24 | 2007-08-16 | Basf Aktiengesellschaft | Pirimidinas 2-substituidas. |
| DK1673349T3 (da) | 2003-09-22 | 2010-10-25 | S Bio Pte Ltd | Benzimidazolderivater: fremstilling og farmaceutiske anvendelser |
| CA2539117A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US8227636B2 (en) | 2004-04-05 | 2012-07-24 | Merck Hdac Research, Llc | Histone deacetylase inhibitor prodrugs |
| CA2601706C (en) | 2005-03-22 | 2016-09-20 | Dana-Farber Cancer Institute, Inc. | Treatment of protein degradation disorders |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| AU2006284403A1 (en) | 2005-08-26 | 2007-03-01 | Methylgene Inc. | Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase |
| CN101300245B (zh) | 2005-11-01 | 2011-06-01 | 住友化学株式会社 | 6，6-二甲基-3-氧杂二环[3.1.0]己烷-2-酮的制造方法 |
| WO2007091703A1 (en) | 2006-02-07 | 2007-08-16 | Astellas Pharma Inc. | N-hydroxyacrylamide compounds |
| JP5441416B2 (ja) | 2006-02-14 | 2014-03-12 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二官能性ヒストンデアセチラーゼインヒビター |
| JP5554988B2 (ja) | 2006-04-07 | 2014-07-23 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| AU2007243519A1 (en) | 2006-04-26 | 2007-11-08 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
| US8304451B2 (en) | 2006-05-03 | 2012-11-06 | President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| US20100278782A1 (en) | 2006-06-12 | 2010-11-04 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
| ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
| SG174790A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Tyrosine kinase inhibitors containing a zinc binding moiety |
| CA2667826C (en) | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP2077999B1 (en) | 2006-10-30 | 2014-07-30 | Chroma Therapeutics Limited | Hydroxamates as inhibitors of histone deacetylase |
| US8518979B2 (en) | 2007-02-21 | 2013-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof |
| JP2010120852A (ja) | 2007-03-09 | 2010-06-03 | Daiichi Sankyo Co Ltd | 新規なジアミド誘導体 |
| TW200924777A (en) | 2007-09-14 | 2009-06-16 | Methylgene Inc | Combination therapy |
| KR101325374B1 (ko) | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
| WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
| US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| JP5665740B2 (ja) | 2008-07-23 | 2015-02-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | デアセチラーゼ阻害剤およびその使用 |
| CN102341108B (zh) | 2009-01-08 | 2015-05-27 | 柯瑞斯公司 | 具有锌结合半族的磷酸肌醇3-激酶抑制剂 |
| WO2010131922A2 (en) | 2009-05-15 | 2010-11-18 | Korea Research Institute Of Chemical Technology | Amide compound, preparation method thereof and pharmaceutical composition comprising same |
| ES2736200T3 (es) | 2009-07-22 | 2019-12-26 | Univ Illinois | Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| EP2638009A4 (en) | 2010-01-08 | 2014-06-11 | Harvard College | FLUORINATED HDAC HEMMER AND USES THEREOF |
| MX2012008553A (es) * | 2010-01-22 | 2012-11-30 | Acetylon Pharmaceuticals Inc | Compuestos de amida inversa como inhibidores de proteina desacetilasa y metodos de uso de los mismos. |
| AU2011255281A1 (en) | 2010-05-21 | 2013-01-10 | Sloan-Kettering Institute For Cancer Research | Selective HDAC inhibitors |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| US8859502B2 (en) * | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| CA2818125A1 (en) | 2010-11-16 | 2012-05-24 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US8404738B2 (en) | 2011-01-21 | 2013-03-26 | Hoffmann-La Roche Inc. | 4-amino-N-hydroxy-benzamides for the treatment of cancer |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| EP2734500A4 (en) * | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| JP2015515279A (ja) * | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| EP2951153B1 (en) | 2013-02-01 | 2019-04-03 | Regenacy Pharmaceuticals, LLC | Selective hdac3 inhibitors |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| WO2014197471A1 (en) | 2013-06-03 | 2014-12-11 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
| US9403779B2 (en) | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
| JP6584391B2 (ja) | 2013-10-10 | 2019-10-02 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ |
| WO2015054197A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
| US9278963B2 (en) | 2013-10-10 | 2016-03-08 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| CR20160200A (es) | 2013-10-11 | 2016-08-29 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores |
| EA201691155A1 (ru) | 2013-12-03 | 2016-09-30 | Эситайлон Фармасьютикалз, Инк. | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств |
| ES2936812T3 (es) | 2013-12-20 | 2023-03-22 | Acetylon Pharmaceuticals Inc | Biomarcadores de histona desacetilasa 6 (HDAC6) en mieloma múltiple |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
-
2015
- 2015-07-06 BR BR112017000301A patent/BR112017000301A2/pt not_active Application Discontinuation
- 2015-07-06 KR KR1020177003321A patent/KR20170044097A/ko unknown
- 2015-07-06 EA EA201790142A patent/EA201790142A1/ru unknown
- 2015-07-06 JP JP2017522324A patent/JP6952602B2/ja active Active
- 2015-07-06 CA CA2954522A patent/CA2954522A1/en not_active Abandoned
- 2015-07-06 MX MX2017000307A patent/MX2017000307A/es unknown
- 2015-07-06 EP EP15818585.0A patent/EP3166603B1/en active Active
- 2015-07-06 WO PCT/US2015/039225 patent/WO2016007423A1/en active Application Filing
- 2015-07-06 AU AU2015288060A patent/AU2015288060A1/en not_active Abandoned
- 2015-07-06 SG SG11201700094TA patent/SG11201700094TA/en unknown
- 2015-07-06 CN CN201580047830.2A patent/CN107205988A/zh active Pending
- 2015-07-06 US US14/792,046 patent/US9833466B2/en active Active
-
2017
- 2017-01-05 IL IL249935A patent/IL249935A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524735A5 (ja) | ||
| JP2016532667A5 (ja) | ||
| JP2016536286A5 (ja) | ||
| JP2015078230A5 (ja) | ||
| JP2011102304A5 (ja) | ||
| JP2015024998A5 (ja) | ||
| JP2016501221A5 (ja) | ||
| JP2016521119A5 (ja) | ||
| JP2013509429A5 (ja) | ||
| JP2013518107A5 (ja) | ||
| JP2016515561A5 (ja) | ||
| JP2012255026A5 (ja) | ||
| JP2013032389A5 (ja) | ||
| JP2016518337A5 (ja) | ||
| JP2016508134A5 (ja) | ||
| JP2014221779A5 (ja) | ||
| JP2017537066A5 (ja) | ||
| JP2017514910A5 (ja) | ||
| JP2014521735A5 (ja) | ||
| JP2015518055A5 (ja) | ||
| JP2017518334A5 (ja) | ||
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| JP2015516419A5 (ja) | ||
| JP2014526503A5 (ja) | ||
| JP2014508804A5 (ja) |